Adrixetinib

DB21620InvestigationalSmall molecule

Adrixetinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Adrixetinib is a tyrosine kinase inhibitor. Adrixetinib has a monoisotopic molecular weight...

Mechanism: Pharmacologically active on Macrophage colony-stimulating factor 1 receptor
Curator reviewed
Formula / weight: C₂₅H₂₄F₃N₅O₅ · 531.492 g/mol (avg)

Resolves to

Compound

UNIIJIJ7I9XO8BCAS2394874-66-7ChEMBLCHEMBL5314452ChEBI759159PubChem156440741

Structure

InChIKeyBWUUJXXFCSYLFW-UHFFFAOYSA-NSMILESCCCN1C=C(OCC(F)(F)F)C(=N1)C(=O)NC1=CC=C(OC2=C3C=C(OC)C(OC)=CC3=NC=C2)C=N1

Targets

P07333CSF1R

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Adrixetinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account